Bernstein analyst Lee Hambright has maintained their bullish stance on BSX stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lee Hambright has given his Buy rating due to a combination of factors that highlight Boston Scientific’s promising growth trajectory. The company has set ambitious long-range plans, projecting an organic sales compound annual growth rate of over 10% for 2026-2028, alongside consistent improvements in operating margins and strong free cash flow conversion. These financial targets suggest a robust and sustainable growth outlook for the company.
Furthermore, Boston Scientific’s key franchises, FARAPULSE and WATCHMAN, are performing exceptionally well, with new product launches and expanded indications contributing to their success. The company also boasts a diverse array of growth drivers across its eight business segments, with potential in emerging markets like renal denervation and intravascular lithotripsy. Hambright believes that the current market valuation is reasonable, given the company’s strong growth prospects and potential for leveraged earnings per share growth.
Hambright covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Boston Scientific, and Medtronic. According to TipRanks, Hambright has an average return of 6.8% and a 63.75% success rate on recommended stocks.
In another report released today, Needham also reiterated a Buy rating on the stock with a $121.00 price target.